L-ASPARAGINASA EFECTOS ADVERSOS PDF

Efectos secundarios del tratamiento para la leucemia linfoblástica aguda .. ( PEG-L asparaginasa; Oncaspar®) administrada por inyección. O Vincristina. L-asparaginase, definition: alkylating anticancer drug used in the treatment of L -asparaginasa, definition: fármaco alquilante antineoplásico, utilizado para el Los efectos secundarios más comunes son nauseas, vómitos. y otros efectos adversos de este grupo de fármacos, ya que estos pacientes los efectos citotóxicos de la quimioterapia son mediados por diversos . Actinomicina D, metotrexato, andrógenos, L-asparaginasa, procarbazina, vincristina.

Author: Doutilar Kajikora
Country: Samoa
Language: English (Spanish)
Genre: Health and Food
Published (Last): 18 February 2018
Pages: 496
PDF File Size: 14.86 Mb
ePub File Size: 18.66 Mb
ISBN: 633-7-76646-273-2
Downloads: 78596
Price: Free* [*Free Regsitration Required]
Uploader: Groshicage

For these items you should use the filters and not add them to your search terms in the text l-asparaginaaa. Title of l-asapraginasa trial for lay people, in easily understood, i.

Subjects must have fully recovered from the acute toxic effects of all previous chemotherapy, immunotherapy, or radiotherapy treatment before enrollment. Trials with results Trials without results Clear advanced search filters.

Subjects must have a serum creatinine level that is? Known allergy to any of the drugs used in the study. L-asparaginasw allergy to Captisol a cyclodextrin derivative used to solubilize carfilzomib; for a complete listing of Captisol-enabled drugs, see the Ligand Pharmaceuticals, Inc.

Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial. Time to toxicity will be evaluated to differentiate single-agent carfilzomib from carfilzomib in combination with induction chemotherapy?

  BLUEGIGA WT41 PDF

Medicinas para Quimioterapia – Nombres de Medicina

Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Karnofsky or Lansky scores? Phase 1b – To assess the safety and tolerability of carfilzomib, alone and in combination with induction chemotherapy, for the treatment of children with relapsed or refractory acute lymphoblastic leukemia ALL -To determine the maximum tolerated dose MTD of carfilzomib in combination with induction chemotherapy.

The IMP has been designated in this indication as an orphan drug in the Community. A group of cancers that usually begins in the bone marrow and results in high numbers of abnormal white blood cells.

Age 18 years or younger at the time of study treatment initiation. Active treatment for graft-versus-host disease 6. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.

Positive culture for bacteria or fungus within 14 days of the initiation of therapy 7. Clear advanced search filters. Trials with results Trials without results. Relapsed or Refractory Acute Lymphoblastic Leukemia. How to l-qsparaginasa [pdf]. Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible.

  JONATHAN CULLER ON DECONSTRUCTION PDF

IMP with orphan designation in the indication.

Clinical Trials Register

The trial involves single site in the Member State concerned. Combination product that includes a device, but does not involve an Advanced Therapy.

Pneumonia AND sponsor name. Adequate liver function, defined as l-asparahinasa of the following: The duration of this interval must be approved by the Onyx study medical monitor.

l-asparaginasa efectos adversos pdf

Restricciones de tratamientos previos: Date on which this record was first entered in the EudraCT database:. Son aptos los sujetos que hayan sufrido una alergia previa a la asparaginasa PEG pero que puedan recibir Erwinia.

Cancer AND drug name. Subjects are under 18 years old. EU Clinical Trials Register. Adcersos sujetos deben haber finalizado todo tipo de inmunoterapia activa p.

Review by the Competent Authority or Ethics Committee in the country concerned. Committee on Advanced therapies CAT has issued efdctos classification for this product.